Fc Receptor Targeting Reduces Bone Disease in a Pre-Clinical Model of Multiple Myeloma

被引：0
|
作者：
Williams, Mark T. [1 ]
Thuemmler, Katya [1 ]
Kitson, Susan [1 ]
Soutar, Richard [2 ]
Goodyear, Carl S. [1 ]
机构：
[1] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[2] Gartnavel Hosp, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies
    Alcaide, Enrique Gomez
    Krishnarajah, Sinduya
    Junker, Fabian
    VACCINES, 2021, 9 (04)
  • [12] Pre-clinical evaluation of bortezomib, doxorubicin, dexamethasone, and lenalidomide in multiple myeloma (MM)
    Hari, M.
    Hector-Word, Z.
    Lebovic, D.
    Soengas, M.
    Jakubowiak, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [13] An antisense platform for the pre-clinical development of novel LncRNA inhibitors in multiple myeloma
    Morelli, Eugenio
    Gulla, Annamaria
    Liu, Na
    Johnstone, Megan
    Vinaixa, Delaney
    Gramegna, Doriana
    Wen, Kenneth
    Tai, Yu-Tzu
    Chauhan, Dharminder
    Samur, Mehmet
    Shammas, Masood
    Fulciniti, Mariateresa
    Gryaznov, Sergei
    Anderson, Kenneth
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S94 - S95
  • [14] Pre-clinical studies in support of the clinical development of Aplidin® (APL) for the treatment of Multiple Myeloma (MM).
    Mitsiades, CS
    Mitsiades, N
    McMullan, CJ
    Faircloth, G
    Martin, JAL
    Otero-Serrano, G
    Anderson, KC
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6204S - 6204S
  • [15] Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.
    Lawson, M. A.
    Coulton, L.
    Ebetino, F. H.
    Gallagher, O.
    Prideaux, M.
    Vanderkerken, K.
    Croucher, P. I.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S137 - S137
  • [16] Pre-clinical studies in support of the clinical development of aplidin® (APL) for the treatment of multiple myeloma (MM).
    Mitsiades, CS
    McMullan, CJ
    Mitsiades, N
    Faircloth, G
    Lopez-Martin, JA
    Otero-Serano, G
    Anderson, KC
    BLOOD, 2003, 102 (11) : 74A - 74A
  • [17] Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
    Drent, Esther
    Groen, Richard W. J.
    Noort, Willy A.
    Themeli, Maria
    van Bueren, Jeroen J. Lammerts
    Parren, Paul W. H. I.
    Kuball, Jurgen
    Sebestyen, Zsolt
    Yuan, Huipin
    de Bruijn, Joost
    van de Donk, Niels W. C. J.
    Martens, Anton C. M.
    Lokhorst, Henk M.
    Mutis, Tuna
    HAEMATOLOGICA, 2016, 101 (05) : 616 - 625
  • [18] Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
    Bernstein, Zachary S.
    Kim, E. Bridget
    Raje, Noopur
    CELLS, 2022, 11 (15)
  • [19] GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
    Roumane, Ahlima
    Mcilroy, George D.
    Sommer, Nadine
    Han, Weiping
    Heisler, Lora K.
    Rochford, Justin J.
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [20] Targeting the bone microenvironment in multiple myeloma
    G. David Roodman
    Journal of Bone and Mineral Metabolism, 2010, 28 : 244 - 250
12345